Rheumatoid arthritis: International disparities in access to anti-TNF therapy.
The establishment of new benchmarks for treatment outcomes promises to drive great advances in rheumatoid arthritis therapy, but data on ‘real life’ experience with biologic therapy demonstrate that geographic location influences the stage of disease at which these agents are initiated.